Home » Newsletters » BioWorld Science

BioWorld Science

July 13, 2009

View Archived Issues

Novel DNA repair inhibitors discovered by CSIC and CNIO for cancer treatment

Biovitrum claims leptin receptor antagonists

Somatostatin agonists reported by Biostatin for the treatment of cancer, inflammation and pain

Solvay has launched Creon in the U.S.

Novel PDE4 inhibitor K-34 shows effectiveness in chronic dermatitis in vivo

Novel monoclonal antibody against CD123 shows clinical potential in acute myeloid leukemia

Foresight presents preclinical FST-100 data from adenoviral conjunctivitis model

NexMed and Novartis terminate licensing agreement for NM-100060 for onychomycosis

FDA accepts for review NDA for Amylin, Lilly and Alkermes' exenatide in type 2 diabetes

Genfit presents update on phase II clinical trials of GFT-505

NanoBio completes USD 22 million series B financing round

WraSer to market SALVAT's Cetraxal for acute otitis externa in the U.S.

Genmab completes enrollment in pivotal study of Arzerra in CLL

Schering-Plough receives marketing approval in Japan for Remeron/Reflex in MDD

Schering-Plough receives marketing approval in Japan for Asmanex for bronchial asthma

Barusiban and atosiban compared in women undergoing controlled ovarian stimulation

ENGAGE, ENSURE trials show efficacy of fertility hormone corifollitropin alfa

Hsp90-targeted therapy potentially useful in triple-negative breast cancer

PDK-1 inhibitor OSU-03012 shows potential in benign and malignant schwanommas

Allon reports phase II davunetide intranasal results in schizophrenia

Amarin receives SPA agreement from FDA for phase III AMR-101 trial

Dharma reports results for drug delivery system with lidocaine and epinephrine

Yondelis approved in the Philippines for ovarian cancer and soft tissue sarcoma

Alimta approved in Europe as maintenance therapy for non-squamous NSCLC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...